Save Product
Product Details
Synonyms
CD70, CD27LG, TNFSF7, TNFSF7G, CD27L
Source
PE-Labeled Human CD27 Ligand Protein, His Tag (CDL-HP246) is produced via conjugation of PE to Human CD27 Ligand Protein, His Tag with a new generation site-specific technology under Star Staining labeling platform. Human CD27 Ligand Protein, His Tag is expressed from human 293 cells (HEK293). It contains AA Ser 52 - Pro 193 (Accession # P32970-1).
Predicted N-terminus: His
Molecular Characterization
This protein carries a polyhistidine tag at the N-terminus.
Conjugate
PE
Excitation Wavelength: 488 nm / 561 nm
Emission Wavelength: 575 nm
Purity
>90% as determined by SDS-PAGE.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, 0.2% BSA, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please protect from light and avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Evaluation of CAR expression
FACS Analysis of Anti-CD27 Ligand CAR Expression
5e5 of anti-CD27 Ligand CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human CD27 Ligand Protein, His Tag (Cat. No.CDL-HP246) and negative control protein respectively (Fig. C and B), and non-transfected 293 cells were used as a control (Fig. A). PE signal was used to evaluate the binding activity (QC tested).
Protocol
Customer Reviews Writing Reviews
Background
Recent Advances
Drug Development Progress- English Name：
CD70 antigen
- Category：
- Approved Drugs：
0 Details
- Drugs in Clinical Trials：
37 Details
- Highest Development Stage：
Phase 2 Clinical
Contact Us
メールアドレス
order.jp@acrobiosystems.com
お問い合わせ
グローバル：+1 800-810-0816(Toll Free)
Drug Candidate Licensing
